Advancing non-small cell lung cancer treatment: the power of combination immunotherapies

被引:0
|
作者
Wu, Yuanlin [1 ]
Yu, Guangmao [1 ]
Jin, Ketao [2 ]
Qian, Jun [3 ]
机构
[1] Shaoxing Peoples Hosp, Dept Thorac Surg, Shaoxing, Zhejiang, Peoples R China
[2] Westlake Univ, Affiliated Hangzhou Peoples Hosp 1, Sch Med, Dept Gastrointestinal Colorectal & Anal Surg, Hangzhou, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Xinchang Peoples Hosp, Affiliated Xinchang Hosp, Dept Colorectal Surg, Xinchang, Zhejiang, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
non-small cell lung cancer; immunotherapy; combination therapy; cancer vaccines; tumor microenvironment; TUMOR-INFILTRATING LYMPHOCYTES; IMMUNE-CHECKPOINT INHIBITOR; TYROSINE KINASE INHIBITORS; REGULATORY T-CELLS; PD-L1; EXPRESSION; ADVANCED NSCLC; OPEN-LABEL; PHASE-III; 1ST-LINE NIVOLUMAB; TARGETED THERAPIES;
D O I
10.3389/fimmu.2024.1349502
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Non-small cell lung cancer (NSCLC) remains an unsolved challenge in oncology, signifying a substantial global health burden. While considerable progress has been made in recent years through the emergence of immunotherapy modalities, such as immune checkpoint inhibitors (ICIs), monotherapies often yield limited clinical outcomes. The rationale behind combining various immunotherapeutic or other anticancer agents, the mechanistic underpinnings, and the clinical evidence supporting their utilization is crucial in NSCLC therapy. Regarding the synergistic potential of combination immunotherapies, this study aims to provide insights to help the landscape of NSCLC treatment and improve clinical outcomes. In addition, this review article discusses the challenges and considerations of combination regimens, including toxicity management and patient selection.
引用
收藏
页数:31
相关论文
共 50 条
  • [21] Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer
    Mattson, K
    Saarinen, A
    Jekunen, A
    SEMINARS IN ONCOLOGY, 1997, 24 (04) : S5 - S8
  • [22] The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer
    Alexander, Mariam
    Ko, Brian
    Lambert, Remy
    Gadgeel, Shirish
    Halmos, Balazs
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2020, 14 (02) : 137 - 147
  • [23] Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer
    Tanaka, Kentaro
    Chamoto, Kenji
    Saeki, Sho
    Hatae, Ryusuke
    Ikematsu, Yuki
    Sakai, Kazuko
    Ando, Nobuhisa
    Sonomura, Kazuhiro
    Kojima, Shinsuke
    Taketsuna, Masanori
    Kim, Young Hak
    Yoshida, Hironori
    Ozasa, Hiroaki
    Sakamori, Yuichi
    Hirano, Tomoko
    Matsuda, Fumihiko
    Hirai, Toyohiro
    Nishio, Kazuto
    Sakagami, Takuro
    Fukushima, Masanori
    Nakanishi, Yoichi
    Honjo, Tasuku
    Okamoto, Isamu
    SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (675)
  • [24] Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancer
    Pujol, JL
    Quantin, X
    Choma, D
    Jacot, W
    Khial, F
    LUNG CANCER, 2002, 38 : S57 - S60
  • [25] Microwave Ablation in Combination with Chemotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer
    Zhigang Wei
    Xin Ye
    Xia Yang
    Aimin Zheng
    Guanghui Huang
    Wenhong Li
    Xiang Ni
    Jiao Wang
    Xiaoying Han
    CardioVascular and Interventional Radiology, 2015, 38 : 135 - 142
  • [26] Curative efficacy of thalidomide in combination with nedaplatin in the treatment of non-small cell lung cancer
    徐成
    China Medical Abstracts(Internal Medicine), 2016, 33 (01) : 33 - 33
  • [27] Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer
    Valmori, Danila
    Ayyoub, Maha
    ONCOIMMUNOLOGY, 2016, 5 (04):
  • [28] Diagnosis and treatment of lung cancer - Non-small cell lung cancer, small cell lung cancer and carcinoids
    End A.
    European Surgery, 2006, 38 (1) : 45 - 53
  • [29] On the pharmacogenetics of non-small cell lung cancer treatment
    Santarpia, Mariacarmela
    Rolfo, Christian
    Peters, G. J.
    Leon, Leticia G.
    Giovannetti, Elisa
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 307 - 317
  • [30] Pembrolizumab for the treatment of non-small cell lung cancer
    Muller, Mirte
    Schouten, Robert D.
    De Gooijer, Cornedine J.
    Baas, Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (05) : 399 - 409